<DOC>
	<DOCNO>NCT01602159</DOCNO>
	<brief_summary>This prospective randomized control trial compare clinical improvement , cost effectiveness patency rate new improve Nitinol stent open bypass surgery superficial femoral artery disease . Secondary outcome also include compare quality life , re-intervention rate , mortality , morbidity time return work regular activity . Patients superficial femoral artery lesion consider . Patients TASC II A lesion randomize treat PTA/stenting standard care . Patients TASC II B C lesion prospectively randomize either receive open bypass stenting . Patients TASC D lesion treat open bypass surgery angiography . The investigator collect pre-procedure , peri-procedural clinical follow-up data enrol patient .</brief_summary>
	<brief_title>Revascularization With Open Bypass Versus Angioplasty STenting Lower Extremity Trial ( ROBUST )</brief_title>
	<detailed_description />
	<criteria>Clinical Inclusion : 1 . Must least 18 year age . 2 . Patient informed nature study , provide write informed consent , approve appropriate Institutional Review Board ( IRB ) /Medical Ethics Committee ( MEC ) respective clinical site . 3 . Symptomatic patient evidence IC CLI . 4 . Patient fail maximized medical treatment exercise program . 5 . Patient rest ABI &lt; 0.9 abnormal exercise ABI rest ABI normal.Patient noncompressible artery ( ABI &gt; 1.2 ) must TBI &lt; 0.8 . 6 . Patient de novo restenotic lesion ( ) &gt; 50 % stenosis document angiographically . 7 . Patient agree return require clinical contact follow study enrollment . 8 . Patient childbearing potential negative pregnancy test within one week prior study procedure . Anatomical Inclusion : 1 . Patient SFA lesion 2 . At least one tibial vessel runoff &lt; 50 % stenosis 3 . Lesion start start least 1 cm distal deep femoral artery 4 . Lesion end least 3 cm knee joint 5 . Target vessel reference diameter &gt; 3 mm &amp; &lt; 6.5 mm Clinical exclusion : 1 . Known allergic reaction anesthesia able overcome medication . 2 . Known allergic reaction contrast able overcome medication . 3 . Known history intolerance study medicate include ASA , clopidogrel , ticlopidine . 4 . Bleeding disorder refuse blood transfusion . 5 . Prior stenting bypass SFA ( prior PTA exclusion criterion ) 6 . Unstable angina , recent MI within month 7 . Malignancy condition limit life expectancy &lt; 5 year . 8 . Renal insufficiency ( serum Cr &gt; 2.0 ) 9 . Patient condition precludes proper angiographic assessment make percutaneous arterial access unsafe ( e.g. , morbid obesity ) . Anatomic Exclusion : 1 . Lesion &lt; 1 cm origin DFA 2 . Lesion &lt; 3 cm knee joint 3 . Chronic total occlusion SFA &gt; 20cm . 4 . Chronic total occlusion CFA . 5 . Proximal trifurcation occlusion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Claudication</keyword>
	<keyword>SFA</keyword>
	<keyword>Open Bypass</keyword>
	<keyword>Angioplasty</keyword>
	<keyword>Stenting</keyword>
</DOC>